close
Add to watchlist
Pain Therapeutics Inc (PTIE) Healthcare, Biotechnology & Drugs
Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and another abuse-resistant opioid painkiller. The company was founded in 1998 and is based in San Mateo, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.80 |
| Volume | 72805 |
| Volume Avg | 124887 |
| 52 Week High | 10.45 |
| 52 Week Low | 3.28 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.06 |
| EPS change Q/Q | -100% |
| EPS change Q/Q Yr ago | -100% |
| EPS change Q/Q next Q est | 0% |
| EPS change Y/Y | -76% |
| REV change Q/Q | -60% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |